Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05793112 · ClinicalTrials.gov registry record · Phase 4
INF108F in Infants With Food Protein Induced Proctocolitis
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT05793112: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT05793112 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05793112, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Single-center, randomized, double-blind, placebo-controlled trail evaluating INF108F in breastfed infants with FPIAP
Interventions
- DRUG Placebo
- DRUG INF108F probiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-09-09 |
| Est. Completion | 2024-09-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05793112
The ClinicalTrials.gov registry entry for NCT05793112 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05793112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05793112 about?
NCT05793112 is a clinical study titled "INF108F in Infants With Food Protein Induced Proctocolitis". Single-center, randomized, double-blind, placebo-controlled trail evaluating INF108F in breastfed infants with FPIAP
What is the current status of trial NCT05793112?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-09-09. Estimated completion is 2024-09-27.
What interventions are being tested in trial NCT05793112?
The interventions under investigation include: Placebo (DRUG), INF108F probiotic (DRUG).
Who is sponsoring clinical trial NCT05793112?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.